Miyata Toshio, Takizawa Shunya
Division of Nephrology, Hypertension and Metabolism, Tokai University School of Medicine, Kanagawa, Japan.
Hemodial Int. 2007 Apr;11(2):164-8. doi: 10.1111/j.1542-4758.2007.00164.x.
The rising tide of chronic kidney disease (CKD), especially diabetic nephropathy, has become a worldwide catastrophe. However, therapeutic options to prevent or retard the progression of CKD still remain very limited. The understanding of its molecular mechanisms and the delineation of tools able to modify them are thus of critical importance. The discovery that some antihypertensive agents inhibiting the renin-angiotensin system, such as angiotensin II type 1 receptor blockers, protect the kidney opens new therapeutic perspectives. In this article, we focus on their renoprotective actions beyond blood pressure lowering.
慢性肾脏病（CKD），尤其是糖尿病肾病的不断增加，已成为一场全球性的灾难。然而，预防或延缓CKD进展的治疗选择仍然非常有限。因此，了解其分子机制并确定能够改变这些机制的工具至关重要。一些抑制肾素-血管紧张素系统的抗高血压药物，如血管紧张素II 1型受体阻滞剂，具有肾脏保护作用，这一发现开辟了新的治疗前景。在本文中，我们重点关注它们在降低血压之外的肾脏保护作用。
